HDL Size is More Accurate than HDL Cholesterol to Predict Carotid Subclinical Atherosclerosis in Individuals Classified as Low Cardiovascular Risk

Background Misclassification of patients as low cardiovascular risk (LCR) remains a major concern and challenges the efficacy of traditional risk markers. Due to its strong association with cholesterol acceptor capacity, high-density lipoprotein (HDL) size has been appointed as a potential risk marker. Hence, we investigate whether HDL size improves the predictive value of HDL-cholesterol in the identification of carotid atherosclerotic burden in individuals stratified to be at LCR. Methods and Findings 284 individuals (40–75 years) classified as LCR by the current US guidelines were selected in a three-step procedure from primary care centers of the cities of Campinas and Americana, SP, Brazil. Apolipoprotein B-containing lipoproteins were precipitated by polyethylene glycol and HDL size was measured by dynamic light scattering (DLS) technique. Participants were classified in tertiles of HDL size (<7.57; 7.57–8.22; >8.22 nm). Carotid intima-media thickness (cIMT) <0.90 mm (80th percentile) was determined by high resolution ultrasonography and multivariate ordinal regression models were used to assess the association between cIMT across HDL size and levels of lipid parameters. HDL-cholesterol was not associated with cIMT. In contrast, HDL size >8.22 nm was independently associated with low cIMT in either unadjusted and adjusted models for age, gender and Homeostasis Model Assessment 2 index for insulin sensitivity, ethnicity and body mass index (Odds ratio 0.23; 95% confidence interval 0.07–0.74, p = 0.013). Conclusion The mean HDL size estimated with DLS constitutes a better predictor for subclinical carotid atherosclerosis than the conventional measurements of plasma HDL-cholesterol in individuals classified as LCR.

[1]  Bernd Holleczek,et al.  High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. , 2013, European heart journal.

[2]  Ian Graham,et al.  How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[3]  C. Ehnholm,et al.  Preparation, characterization, and measurement of hepatic lipase. , 1986, Methods in enzymology.

[4]  E. Ros,et al.  Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[5]  M. Jauhiainen,et al.  Determination of human plasma phospholipid transfer protein mass and activity. , 2005, Methods.

[6]  N. Wareham,et al.  High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.

[7]  A. Kontush,et al.  Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[8]  José A Fernández,et al.  Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. , 2009, Biochimica et biophysica acta.

[9]  Samia Mora,et al.  Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.

[10]  V. Dias,et al.  Dual-precipitation method evaluated for determination of high-density lipoprotein (HDL), HDL2, and HDL3 cholesterol concentrations. , 1988, Clinical chemistry.

[11]  D. Freedman,et al.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.

[12]  R. Devries,et al.  Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. , 2003 .

[13]  W. Sluiter,et al.  Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. , 2008, The Journal of clinical endocrinology and metabolism.

[14]  M. Jauhiainen,et al.  Dietary determinants of serum paraoxonase activity in healthy humans. , 2002, Atherosclerosis.

[15]  E. Vicaut,et al.  Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011) , 2012, Cerebrovascular Diseases.

[16]  A. Gebre,et al.  Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. , 1999, Journal of lipid research.

[17]  J. Frohlich,et al.  Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. , 1992, Journal of lipid research.

[18]  R. Dullaart,et al.  Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. , 2003, Clinical laboratory.

[19]  G. Dallinga-Thie,et al.  Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects. , 2011, Atherosclerosis.

[20]  A. Sposito,et al.  Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. , 2011, Atherosclerosis.

[21]  R. Maranhão,et al.  Rapid, simple laser-light-scattering method for HDL particle sizing in whole plasma. , 2004, Clinical chemistry.

[22]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[23]  S. Hazen,et al.  Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[25]  Ji-Young Lee,et al.  Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice Published, JLR Papers in Press, February 1, 2007. , 2007, Journal of Lipid Research.

[26]  A. Jonas,et al.  Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. , 2001, Journal of lipid research.

[27]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[28]  W. J. Johnson,et al.  High Density Lipoprotein Phospholipid Composition Is a Major Determinant of the Bi-directional Flux and Net Movement of Cellular Free Cholesterol Mediated by Scavenger Receptor BI* , 2000, The Journal of Biological Chemistry.

[29]  L. Lagrost,et al.  Determination of the mass concentration and the activity of the plasma cholesteryl ester transfer protein (CETP). , 1998, Methods in molecular biology.

[30]  New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method. , 2006, Diabetes care.

[31]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[32]  S. Yamashita,et al.  Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia DOI 10.1194/jlr.M100349-JLR200 , 2002, Journal of Lipid Research.

[33]  R. Dullaart,et al.  Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins , 2003, European journal of clinical investigation.

[34]  E. Vicaut,et al.  Mannheim Carotid Intima-Media Thickness Consensus (2004–2006) , 2006, Cerebrovascular Diseases.

[35]  H. Kahn,et al.  The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison , 2005, BMC cardiovascular disorders.